(Last Updated On: May 19, 2021)

Authors: Clarisse G. Mendoza, MD, FPDS, Bryan Edgar K. Guevara, MD, FPDS, Cybill Dianne C. Uy, MD, FPDS



  • Immunocompromised patients have a higher risk of developing severe and life-threatening COVID-
    19 infection compared to the general population.
  • The three Philippine FDA-authorized for emergency use COVID-19 vaccines are all non-live vaccines,
    these vaccines may provide benefits for dermatologic patients with immunosuppressed states or who
    are taking immunomodulating medications, upon appropriate advice and counseling.
  • COVID-19 vaccination should not replace transmission prevention measures–i.e. proper mask
    wearing, frequent disinfection, and physical distancing.




1. Coronavirus disease (COVID-19) Pandemic: Numbers at a glance. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Retrieved 19 April 2021.

2. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Heal journa.
2020;13(January):1833-1839. doi: 10.1016/j.jiph.2020.07.014.

3. List of FDA-issued EUA. https://www.fda.gov.ph/list-of-fda-issued-emergency-use-authorization/. Retrieved 19 April 2021.

4. Schwartz RA, et al. COVID-19 and immunosuppressive therapy in dermatology. Dermatologic Therapy. July 2020;e14140. doi: 10.1111/dth.14140

5. Vaccine Types. https://www.vaccines.gov/basics/types. Retrieved 3 March 2021.

6. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. Published online February 26, 2021. doi:10.1001/jama.2021.3199.

7. Gelfand J, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic:
Version 2: Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. Published online
February 27, 2021. doi:10.1016/j.jaad.2020.12.058.

8. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination
in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77:898-904. DOI: 10.1136/annrheumdis-2018-213222.

9. Subesinghe S, Bechman K, Rutherford AI, Goldblatt D, Galloway JB. A systematic review and meta-analysis of anti-rheumatic drugs and
vaccine immunogenicity in rheumatoid arthritis. J Rheumatol. 2018;45:733-744. DOI: 10.3899/jrheum.170710.

10. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory
bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042-1047. DOI: 10.1002/ibd.21800.

11. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with
rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272-279. PMID: 17304653.

12. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid
arthritis. Ann Rheum Dis. 2016;75:687-695. DOI: 10.1136/annrheumdis-2014-207191.

13. Doornekamp L, Goetgebuer RL, Schmitz KS, et al. High immunogenicity to influenza vaccination in Crohn’s disease patients treated with
ustekinumab. Vaccines (Basel). 2020;8:455. DOI: 10.3390/vaccines8030455.

14. Furer V, Zisman D, Kaufman I, et al. Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic
arthritis treated with secukinumab. Vaccine. 2020;38:847-851. DOI: 10.1016/j.vaccine.2019.10.081.

15. Richi P, Martın MD, de Ory F, et al. Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. RMD Open.
2019;5:e001018. DOI: 10.1136/rmdopen-2019-001018.

16. Gomez EV, Bishop JL, Jackson K, Muram TM, Phillips D. Response to tetanus and pneumococcal vaccination following administration of
ixekizumab in healthy participants. BioDrugs. 2017;31:545-554.

17. Chiricozzi, A., Gisondi, P., Bellinato, F., and Girolomoni, G. Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic
Therapies. Vaccines 2020, 8, 769. doi: 10.3390/vaccines8040769.

18. ACR COVID-19 Task Force. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. https://
www.rheumatology.org/About-Us/Newsroom/Press-Releases/ID/1138. Retrieved 5 March 2021.

19. European Academy of Dermatology and Venereology COVID-19 Task Force. Guidance for Autoimmune Blistering Diseases during the COVID-19
pandemic. Updated 14 Jan 2021. https://eadv.org/covid-19/task-force. Retrieved 2 March 2021.

20. American Academy of Dermatology COVID-19 Vaccine administration guidance. https://www.aad.org/member/practice/coronavirus/
vaccines. Retrieved 2 March 2021.

21. de Leon JC, et al. PSAAI Guidelines on the Prevention, Diagnosis and Management of Immediate Severe Allergic Reactions to COVID-19
Vaccines. Published 9 February 2021. Retrieved 3 March 2021.

22. Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Position Statement given by the ASCIA 2 March 2021. Retrieved 2 March

23. Thyssen JP, et al. European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against
COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. http://eprints.whiterose.ac.uk/171529/

More Articles